In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin

N. Gyémánt, H. Engi, Z. Schelz, I. Szatmári, D. Tóth, F. Fülöp, J. Molnár, P. A M De Witte

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Background:The multidrug resistance (MDR) proteins are present in a majority of human tumours. Their activity is important to understand the chemotherapeutic failure. A search for MDR-reversing compounds was conducted among various Betti-base derivatives of tylosin.Methods:Here, we evaluate the in vitro and in vivo P-glycoprotein (P-gp)-modulating activity of the most promising compound N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol (TBN) using human MDR1 gene-transfected and parental L5178 mouse lymphoma cell lines.Results:In vitro experiments showed that TBN dramatically increased the P-gp-mediated cellular uptake of the fluorescent substrate rhodamine 123. Similarly, TBN was found to act as a very potent enhancer of the cytotoxicity of doxorubicin on the resistant cell line. We also provide in vivo evidence using DBA2 mice in support for an increased tumoural accumulation of doxorubicin, without affecting its tissue distribution, resulting in an enhanced antitumoural effect.Conclusion:Our results suggest that TBN is a potent modulator of the P-gp membrane pump and that the compound could be of clinical relevance to improve the efficacy of chemotherapy in MDR cancers.

Original languageEnglish
Pages (from-to)178-185
Number of pages8
JournalBritish Journal of Cancer
Volume103
Issue number2
DOIs
Publication statusPublished - Jul 13 2010

Fingerprint

Tylosin
Multiple Drug Resistance
P-Glycoprotein
Leukemia L5178
Doxorubicin
P-Glycoproteins
Rhodamine 123
Cell Line
Tissue Distribution
Neoplasms
Drug Therapy
Membranes
Genes
In Vitro Techniques

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin. / Gyémánt, N.; Engi, H.; Schelz, Z.; Szatmári, I.; Tóth, D.; Fülöp, F.; Molnár, J.; De Witte, P. A M.

In: British Journal of Cancer, Vol. 103, No. 2, 13.07.2010, p. 178-185.

Research output: Contribution to journalArticle

@article{3ceba028fcec4614b7319e59ca91d00a,
title = "In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin",
abstract = "Background:The multidrug resistance (MDR) proteins are present in a majority of human tumours. Their activity is important to understand the chemotherapeutic failure. A search for MDR-reversing compounds was conducted among various Betti-base derivatives of tylosin.Methods:Here, we evaluate the in vitro and in vivo P-glycoprotein (P-gp)-modulating activity of the most promising compound N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol (TBN) using human MDR1 gene-transfected and parental L5178 mouse lymphoma cell lines.Results:In vitro experiments showed that TBN dramatically increased the P-gp-mediated cellular uptake of the fluorescent substrate rhodamine 123. Similarly, TBN was found to act as a very potent enhancer of the cytotoxicity of doxorubicin on the resistant cell line. We also provide in vivo evidence using DBA2 mice in support for an increased tumoural accumulation of doxorubicin, without affecting its tissue distribution, resulting in an enhanced antitumoural effect.Conclusion:Our results suggest that TBN is a potent modulator of the P-gp membrane pump and that the compound could be of clinical relevance to improve the efficacy of chemotherapy in MDR cancers.",
author = "N. Gy{\'e}m{\'a}nt and H. Engi and Z. Schelz and I. Szatm{\'a}ri and D. T{\'o}th and F. F{\"u}l{\"o}p and J. Moln{\'a}r and {De Witte}, {P. A M}",
year = "2010",
month = "7",
day = "13",
doi = "10.1038/sj.bjc.6605716",
language = "English",
volume = "103",
pages = "178--185",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - In vitro and in vivo multidrug resistance reversal activity by a Betti-base derivative of tylosin

AU - Gyémánt, N.

AU - Engi, H.

AU - Schelz, Z.

AU - Szatmári, I.

AU - Tóth, D.

AU - Fülöp, F.

AU - Molnár, J.

AU - De Witte, P. A M

PY - 2010/7/13

Y1 - 2010/7/13

N2 - Background:The multidrug resistance (MDR) proteins are present in a majority of human tumours. Their activity is important to understand the chemotherapeutic failure. A search for MDR-reversing compounds was conducted among various Betti-base derivatives of tylosin.Methods:Here, we evaluate the in vitro and in vivo P-glycoprotein (P-gp)-modulating activity of the most promising compound N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol (TBN) using human MDR1 gene-transfected and parental L5178 mouse lymphoma cell lines.Results:In vitro experiments showed that TBN dramatically increased the P-gp-mediated cellular uptake of the fluorescent substrate rhodamine 123. Similarly, TBN was found to act as a very potent enhancer of the cytotoxicity of doxorubicin on the resistant cell line. We also provide in vivo evidence using DBA2 mice in support for an increased tumoural accumulation of doxorubicin, without affecting its tissue distribution, resulting in an enhanced antitumoural effect.Conclusion:Our results suggest that TBN is a potent modulator of the P-gp membrane pump and that the compound could be of clinical relevance to improve the efficacy of chemotherapy in MDR cancers.

AB - Background:The multidrug resistance (MDR) proteins are present in a majority of human tumours. Their activity is important to understand the chemotherapeutic failure. A search for MDR-reversing compounds was conducted among various Betti-base derivatives of tylosin.Methods:Here, we evaluate the in vitro and in vivo P-glycoprotein (P-gp)-modulating activity of the most promising compound N-tylosil-1-α-amino-(3-bromophenyl)-methyl-2-naphthol (TBN) using human MDR1 gene-transfected and parental L5178 mouse lymphoma cell lines.Results:In vitro experiments showed that TBN dramatically increased the P-gp-mediated cellular uptake of the fluorescent substrate rhodamine 123. Similarly, TBN was found to act as a very potent enhancer of the cytotoxicity of doxorubicin on the resistant cell line. We also provide in vivo evidence using DBA2 mice in support for an increased tumoural accumulation of doxorubicin, without affecting its tissue distribution, resulting in an enhanced antitumoural effect.Conclusion:Our results suggest that TBN is a potent modulator of the P-gp membrane pump and that the compound could be of clinical relevance to improve the efficacy of chemotherapy in MDR cancers.

UR - http://www.scopus.com/inward/record.url?scp=77954656220&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954656220&partnerID=8YFLogxK

U2 - 10.1038/sj.bjc.6605716

DO - 10.1038/sj.bjc.6605716

M3 - Article

VL - 103

SP - 178

EP - 185

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -